Evidence map›Paper›PMID 33215260›Full record

ArticleApplied microbiology and biotechnology2021

Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them.

Maryam Zamani Sani, Afshar Bargahi, Niloofar Momenzadeh, Parva Dehghani, Maryam Vakili Moghadam, Soheila June Maleki, Iraj Nabipour, Afshin Shirkani, Javad Akhtari, Khashayar Hesamizadeh and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Recent advances in allergen immunotherapy.Chinese medical journal · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Virus-like particle vaccinology, from bench to bedside.Cellular & molecular immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Maryam Zamani SaniDepartment of Biochemistry, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Afshar BargahiDepartment of Biochemistry, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Niloofar MomenzadehThe Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Moallem Street, Bushehr, 7514633196, Iran.
Parva DehghaniThe Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Moallem Street, Bushehr, 7514633196, Iran.
Maryam Vakili MoghadamDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Soheila June MalekiSouthern Regional Research Center, Agricultural Research Service, US Department of Agriculture, New Orleans, LA, USA.
Iraj NabipourThe Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Moallem Street, Bushehr, 7514633196, Iran.
Afshin ShirkaniAllergy and Clinical Immunology Department, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Javad AkhtariToxoplasmosis Research Center, Department of Medical Nanotechnology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Khashayar HesamizadehDepartment of Virology, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran.
Sahel HeidariDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Fatemeh OmraniThe Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Moallem Street, Bushehr, 7514633196, Iran.
Samad AkbarzadehDepartment of Biochemistry, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Mohsen MohammadiThe Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Moallem Street, Bushehr, 7514633196, Iran. mmohamadi1986@yahoo.com.ORCID http://orcid.org/0000-0002-4085-9288
Biotechnology Research Center · IRBushehr University of Medical Sciences · IRIran University of Medical Sciences · IRAgricultural Research Service · USMazandaran University of Medical Sciences · IR

Funding

Bushehr University of Medical Sciences code:1218
6 · The paper itself

Abstract

Chimeric virus-like particles (VLPs) were developed as a candidate for allergen-specific immunotherapy. In this study, hepatitis B core antigen (HBcAg) that genetically fused to Chenopodium album polcalcin (Che a 3)-derived peptide was expressed in E. coli BL21, purified, and VLP formation was evaluated using native agarose gel electrophoresis (NAGE) and transmission electron microscopy (TEM). Chimeric HBc VLPs were characterized in terms of their reactivity to IgE, the induction of blocking IgG and allergen-specific IgE, basophil-activating capacity, and Th1-type immune responses. Results from IgE reactivity and basophil activation test showed that chimeric HBc VLPs lack IgE-binding capacity and basophil degranulation activity. Although chimeric HBc VLPs induced the highest level of efficient polcalcin-specific IgG antibody in comparison to those induced by recombinant Che a 3 (rChe a 3) mixed either with HBc VLPs or alum, they triggered the lowest level of polcalcin-specific IgE in mice following immunization. Furthermore, in comparison to the other antigens, chimeric HBc VLPs produced a polcalcin-specific Th1 cell response. Taken together, genetically fusion of allergen derivatives to HBc VLPs, in comparison to a mix of them, may be a more effective way to induce appropriate immune responses in allergen-specific immunotherapy. KEY POINTS: • The insertion of allergen-derived peptide into major insertion region (MIR) of hepatitis B virus core (HBc) antigen resulted in nanoparticles displaying allergen-derived peptide upon its expression in prokaryotic host. • The resultant VLPs (chimeric HBc VLPs) did not exhibit IgE reactivity with allergic patients' sera and were not able to degranulate basophils. • Chimeric HBc VLPs dramatically improved protective IgG antibody response compared with those induced by allergen mixed either with HBc VLPs or alum. • Chimeric HBc VLPs induced Th1 responses that were counterparts of Th2 responses (allergic). • Chimeric HBc VLPs increased IgG2a/ IgG1 ratio and the level of IFN-γ compared to those induced by allergen mixed with either HBc VLPs or alum. Graphical Abstract.

Indexed as

AllergensEscherichia coliAnimalsHepatitis B Core AntigensHumansImmunizationImmunoglobulin EMiceMice, Inbred BALB CAllergensHepatitis B Core AntigensImmunoglobulin EChenopodium album polcalcinChimeric viral-like particleVaccine designVirus-like particle

Identifiers

PMID33215260
OpenAlexW3104497966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.